Dr Nveed I Chaudhary Founder & Director NexCentra Consulting Ltd.
Scientific & Regulatory Strategist | Communicator | Advocate for Harm Reduction | Aligned Innovation
Dr. Nveed Chaudhary is a globally respected scientific leader with over 20 years of experience in pharmaceutical innovation, regulatory strategy, and the development of high-impact consumer health products.
With a PhD in Respiratory Medicine and a foundational background in Pharmacology and Physiology, Dr. Chaudhary has built a reputation for combining rigorous scientific insight with a deep understanding of regulatory frameworks, from pharmaceutical licensing (MAA, CTA) to consumer product safety and the MRTP/PMTA pathway for tobacco-alternative products.
His work consistently bridges the gap between bench science and public health impact, particularly in the fields of inhaled therapeutics, nicotine replacement technologies, and novel delivery systems.
Dr. Chaudhary has been directly involved in the development and global launch of several landmark nicotine products designed for population-level tobacco harm reduction, including IQOS (Philip Morris International), myBlu and Pulze (Imperial Brands), as well as oral nicotine pouches. In addition to these publicly recognised innovations, he has consulted on a wide portfolio of confidential projects across tobacco harm reduction, functional inhalers, and regulated consumer health goods.
Earlier in his career, Dr. Chaudhary played a pivotal role at Boehringer Ingelheim in the development of Nintedanib, a first-in-class antifibrotic treatment for idiopathic pulmonary fibrosis (IPF). Approved in the US (FDA), EU (EMA), Japan (PMDA), and UK (MHRA) Nintedanib transformed the prognosis for IPF patients,slowing disease progression and improving quality of life where treatment options had previously been limited. He is listed as an inventor on several patents for Nintedanib, now considered a cornerstone therapy in fibrotic lung disease.
In 2024, Dr. Chaudhary founded the Jibraan Chaudhary Sepsis Research Foundation, a UK-registered charity established in memory of his son, who tragically passed away from sepsis associated with leukemia treatment. The foundation funds research into leukemia-associated infections and drives awareness of sepsis as an urgent and under-recognised medical challenge. This work reflects his deep personal commitment to improving outcomes for vulnerable patients.
Most recently based in the UAE, Dr. Chaudhary spearheaded efforts to establish a GMP- and ISO-compliant manufacturing platform for medicinally regulated nicotine pouches and inhaled therapies, working closely with government and private partners to align product development with international standards and public health goals.
Now as founder of NexCentra Consulting, Dr. Chaudhary continues to advise multinational corporations, startups, and public health agencies on product innovation, regulatory approval, and harm reduction strategy. Known for his discretion, credibility, and results-driven approach, he is a trusted partner to organisations navigating the complex path to bringing regulated, science-based products to market. With numerous scientific publications, patents, and successful product launches to his name, he remains deeply commited to using science to serve society transforming research into real-world solutions that improve lives.
Since June 2025, Nveed has been the Chair of the Science and Standards Committee at GINN (Global Institute for Novel Nicotine), where the goal is to create standards and influence regulations which safeguard the industry and safeguard consumers.
NexCentra Consulting 